STAMPEDE

Survival Not Improved by Adding Radiotherapy in All Newly Diagnosed Men with Metastatic Prostate Cancer

According to the results of the STAMPEDE trial.1 adding radiotherapy (radiation) to the current standard-of-care androgen deprivation therapy (ADT of hormone therapy) did not improve the overall survival in all men who are newly diagnosed metastatic prostate cancer.   

Ablative Radiation Increases Survival in Some Newly Diagnosed Men with Metastatic Prostate Cancer

In certain men newly diagnosed with Advanced Prostate Cancer, or metastatic prostate cancer debunking the tumor with radiation can increase survival advantage.